Core Insights - Transcarent has completed the acquisition of Accolade for approximately $621 million, enhancing its digital health offerings [1][2] - Accolade shareholders received $7.03 per share in cash, and the company's stock will no longer be traded on Nasdaq [2] - Transcarent aims to create a new health and care experience by integrating Accolade's capabilities, emphasizing the benefits of their combined resources [3] Company Overview - Transcarent provides at-risk pricing models to self-insured employers, facilitating quick access to care and benefits navigation for employees [3] - As of May, Transcarent has raised around $450 million, achieving a valuation of $2.2 billion [3] - The company was recognized on CNBC's Disruptor 50 list last year, highlighting its innovative approach in the digital health sector [3]

Core Viewpoint - Accolade stockholders have approved the merger with Transcarent, with the transaction expected to close in the second quarter of 2025, subject to regulatory approvals [1][2]. Group 1: Merger Details - The merger was approved during a special meeting of Accolade stockholders [1]. - The transaction is anticipated to be completed in the second quarter of 2025, pending customary closing conditions and state regulatory approvals [2]. - Following the merger, Accolade will transition to a privately held company, and its common stock will no longer be publicly traded [2]. Group 2: Advisory Information - Evercore is the exclusive financial advisor for Transcarent, while Morgan Stanley & Co LLC serves as the financial advisor for Accolade [3]. - Legal advisory for Transcarent is provided by Wilson Sonsini Goodrich & Rosati, and Cooley LLP advises Accolade [3]. Group 3: Company Profiles - Accolade is a Personalized Healthcare company that offers a range of healthcare solutions, achieving consumer satisfaction ratings exceeding 90% [4]. - Transcarent focuses on providing accessible, high-quality healthcare experiences, utilizing generative AI for benefits navigation and clinical guidance [5][6].